

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
May 20-21, 2025

**MEETING ROSTER**

---

---

**ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)**

**Jessica Seo, PharmD, MPH**

Division of Advisory Committee and Consultant Management  
Office of Executive Programs, CDER, FDA

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)**

**Toni K. Choueiri, MD** *(via video conferencing platform;  
May 20 Sessions Only)*

Director, Lank Center for Genitourinary Oncology  
Professor, Harvard Medical School  
Dana-Farber Cancer Institute  
Boston, Massachusetts

**Mark R. Conaway, PhD**  
*(All Sessions)*

Professor, Division of Translational Research and  
Applied Statistics  
Department of Public Health Sciences  
The University of Virginia School of Medicine  
Charlottesville, Virginia

**William J. Gradishar, MD**  
*(May 21 Sessions Only)*

Betsy Bramsen Professor of Breast Oncology and  
Professor of Medicine  
Deputy Director, Clinical Network  
Director, Maggie Daley Center for Women's Cancer Care  
Robert H. Lurie Comprehensive Cancer Center  
Feinberg School of Medicine at  
Northwestern University  
Chicago, Illinois

**Ravi A. Madan, MD**  
*(All Sessions)*

Senior Clinician  
Head, Prostate Cancer Clinical Research Section  
Genitourinary Malignancies Branch  
Center for Cancer Research  
National Cancer Institute  
National Institutes of Health (NIH)  
Bethesda, Maryland

**Daniel Spratt, MD** *(All sessions; Acting Chairperson for  
May 21 Sessions)*

Vincent K Smith Chair,  
Department of Radiation Oncology  
Professor of Radiation Oncology and Urology  
University Hospitals Seidman Cancer Center  
Case Western Reserve University  
Cleveland, Ohio

**Neil Vasan, MD, PhD** *(All Sessions; Acting Chairperson  
for May 20 Sessions)*

Assistant Professor  
Director, Breast Cancer Translational Research  
Department of Medicine, New York University (NYU)  
Grossman School of Medicine  
Perlmutter Cancer Center, NYU Langone Health  
New York, New York

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Non-Voting)**

**Tara L. Frenkl, MD, MPH**

*(May 20 Sessions and May 21 Morning Session Only)*  
Senior Vice President, Head of Global Medical Strategy  
and Evidence Generation  
Bayer Pharmaceuticals  
Whippany, New Jersey

**Craig Tendler, MD** *(May 21 Afternoon Session Only)*

Vice President, Oncology Clinical Development,  
Diagnostics and Global Medical Affairs,  
Johnson & Johnson (retired)  
President, Tendler Biotech Consulting  
Teaneck, New Jersey

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
May 20-21, 2025

**MEETING ROSTER (cont.)**

---

---

**TEMPORARY MEMBERS (Voting)**

**Mark W. Ball, MD, FACS**

*(May 21 Morning Session Only)*

Associate Research Physician (Associate Professor)  
Associate Program Director,  
Urologic Oncology Fellowship  
Urologic Oncology Branch  
National Cancer Institute, NIH  
Bethesda, Maryland

**Isla P. Garraway, MD, PhD**

*(May 21 Morning Session Only)*

Professor and Director of Research,  
Department of Urology  
Member, Jonsson Comprehensive Cancer Center  
David Geffen School of Medicine at  
University of California, Los Angeles  
Staff Urologist and Principal Investigator,  
Veterans Affairs (VA) Greater Los Angeles  
Healthcare System  
Los Angeles, California

**Julie Graff, MD**

*(May 21 Afternoon Session Only)*

Staff Oncologist  
VA Portland Health Care System  
Professor of Medicine  
Oregon Health & Science University  
Portland, Oregon

**Colette Johnston** *(via video conferencing platform;*

*Patient Representative;*

*May 21 Morning Session Only)*

Moab, Utah

**Terrence “Terry” Kungel, MBA**

*(Patient Representative;*

*May 21 Afternoon Session Only)*

Woolwich, Maine

**Christopher Lieu, MD**

*(May 20 Sessions Only)*

Professor of Medicine  
Associate Director for Clinical Research  
Co-Director, Gastrointestinal (GI) Medical Oncology  
University of Colorado Cancer Center  
Aurora, Colorado

**Paul V. Majkowski, Esq.**

*(Patient Representative;*

*May 20 Morning Session Only)*

Albertson, New York

**Heidi McKean, MD**

*(All Sessions)*

Director, GI Oncology Program  
Community Oncologist  
Avera Medical Oncology and Hematology  
Sioux Falls, South Dakota

**Ajay K. Nooka, MD, MPH**

*(May 20 Morning Session Only)*

Professor, Department of Hematology and  
Medical Oncology  
Director, Myeloma Program  
Associate Director of Clinical Research  
Winship Cancer Institute,  
Emory University School of Medicine  
Atlanta, Georgia

**Joan Durnell Powell**

*(Patient Representative;*

*May 20 Afternoon Session Only)*

MDS Patient Representative and Advocate  
Orange County, California

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
May 20-21, 2025

**MEETING ROSTER (cont.)**

---

---

**FDA PARTICIPANTS (Non-Voting)**

**Richard Pazdur, MD**

*(May 20 Morning Session Only and May 21 Sessions)*

Director  
Oncology Center of Excellence (OCE), FDA

Director (Acting)  
Office of Oncologic Diseases (OOD)  
Office of New Drugs (OND), CDER, FDA

**R. Angelo de Claro, MD**

*(May 20 Sessions Only)*

Deputy Director (Acting)  
OCE, FDA

**Margret Merino, MD**

*(May 20 Morning Session Only)*

Clinical Team Leader  
DHM II, OOD, OND, CDER, FDA

**Bindu Kanapuru, MD**

*(May 20 Afternoon Session Only)*

Supervisory Associate Director for  
Therapeutic Review  
DHM II, OOD, OND, CDER, FDA

**Laleh Amiri-Kordestani, MD**

*(May 21 Sessions Only)*

Director  
Division of Oncology 1 (DO1)  
OOD, OND, CDER, FDA

**Sundeep Agrawal, MD**

*(May 21 Morning Session Only)*

Clinical Team Leader  
Genitourinary Malignancies  
DO1, OOD, OND, CDER, FDA

**Jaleh Fallah, MD**

*(May 21 Afternoon Session Only)*

Clinical Team Leader (Acting)  
Genitourinary Malignancies  
DO1, OOD, OND, CDER, FDA

**Nicole Gormley, MD**

*(May 20 Sessions Only)*

Director  
Division of Hematologic Malignancies II (DHM II)  
OOD, OND, CDER, FDA

**Nicholas Richardson, DO, MPH**

*(May 20 Sessions Only)*

Deputy Director  
DHM II, OOD, OND, CDER, FDA

**Nicole Sunseri, MD, PhD**

*(May 20 Morning Session Only)*

Clinical Reviewer  
DHM II, OOD, OND, CDER, FDA

**Paval Aggarwal, DO, MS**

*(May 20 Afternoon Session Only)*

Clinical Reviewer  
DHM II, OOD, OND, CDER, FDA

**Daniel Suzman, MD**

*(May 21 Sessions Only)*

Deputy Director  
DO1, OOD, OND, CDER, FDA

**Brian Heiss, MD**

*(May 21 Morning Session Only)*

Clinical Reviewer  
Genitourinary Malignancies  
DO1, OOD, OND, CDER, FDA

**William Maguire, MD, PhD**

*(May 21 Afternoon Session Only)*

Clinical Reviewer  
Genitourinary Malignancies  
DO1, OOD, OND, CDER, FDA